CGEM
Cullinan Oncology, Inc. [CGEM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CGEM Stock Summary
In the News
CGEM Financial details
Company Rating
Neutral
Market Cap
717.9M
Income
-153.16M
Revenue
0
Book val./share
10.6
Cash/share
10.91
Dividend
-
Dividend %
-
Employees
85
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.93
Forward P/E
-
PEG
0.12
P/S
-
P/B
0.98
P/C
1.64
P/FCF
-3.23
Quick Ratio
19.9
Current Ratio
20.33
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
-3.71
EPS next Y
-
EPS next Q
-
EPS this Y
-250%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-39.13%
-
-
-
-
SMA20
6.25%
SMA50
-
SMA100
88.89%
Inst Own
56.38%
Inst Trans
0.62%
ROA
-32%
ROE
-31%
ROC
-0.38%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.64-19.68
52W High
-5.89%
52W Low
+155.43%
RSI
60
Rel Volume
2.88
Avg Volume
431.84K
Volume
1.24M
Perf Week
4.81%
Perf Month
9.36%
Perf Quarter
110.35%
Perf Half Y
100.45%
-
-
-
-
Beta
0.326
-
-
Volatility
0.52%, 0.66%
Prev Close
0%
Price
17.88
Change
-0.72%
CGEM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.43 | 0 | 0 | |
| Net income per share | -0.46 | -1.17 | -1.47 | 2.46 | -3.69 | |
| Operating cash flow per share | -0.48 | -0.68 | -0.98 | -2.8 | -3.23 | |
| Free cash flow per share | -0.48 | -0.68 | -0.99 | -2.83 | -3.24 | |
| Cash per share | 2.27 | 4.83 | 14.94 | 19.07 | 11.24 | |
| Book value per share | -0.94 | -1.78 | 9.54 | 11.85 | 10.92 | |
| Tangible book value per share | -0.92 | -1.75 | 9.6 | 11.85 | 10.92 | |
| Share holders equity per share | -0.94 | -1.78 | 9.54 | 11.85 | 10.92 | |
| Interest debt per share | 0 | 0 | 0 | -12.34 | 0.09 | |
| Market cap | 1.3B | 1.3B | 683.43M | 476.48M | 423.39M | |
| Enterprise value | 1.24B | 1.13B | 252.56M | -68.45M | 328.55M | |
| P/E ratio | -64.96 | -25.6 | -10.51 | 4.28 | -2.76 | |
| Price to sales ratio | 0 | 0 | 36.08 | 0 | 0 | |
| POCF ratio | -62.28 | -43.72 | -15.74 | -3.76 | -3.15 | |
| PFCF ratio | -62.23 | -43.7 | -15.52 | -3.73 | -3.15 | |
| P/B Ratio | -31.92 | -16.76 | 1.62 | 0.89 | 0.93 | |
| PTB ratio | -31.92 | -16.76 | 1.62 | 0.89 | 0.93 | |
| EV to sales | 0 | 0 | 13.33 | 0 | 0 | |
| Enterprise value over EBITDA | -55.78 | -18.78 | -3.72 | 0.17 | -1.73 | |
| EV to operating cash flow | -59.26 | -38.07 | -5.82 | 0.54 | -2.45 | |
| EV to free cash flow | -59.2 | -38.06 | -5.74 | 0.54 | -2.44 | |
| Earnings yield | -0.02 | -0.04 | -0.1 | 0.23 | -0.36 | |
| Free cash flow yield | -0.02 | -0.02 | -0.06 | -0.27 | -0.32 | |
| Debt to equity | 0 | 0 | 0 | 0.01 | 0.01 | |
| Debt to assets | 0 | 0 | 0 | 0.01 | 0.01 | |
| Net debt to EBITDA | 2.85 | 2.79 | 6.34 | 1.33 | 0.5 | |
| Current ratio | 39.67 | 14.82 | 25.25 | 21.09 | 17.07 | |
| Interest coverage | 0 | 0 | 0 | -0.26 | 0 | |
| Income quality | 0.97 | 0.5 | 0.64 | -1.16 | 0.88 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 1.54 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 3.05 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | -0.03 | 0 | 0 | |
| Capex to depreciation | -0.29 | -0.16 | -11.12 | -12.18 | -0.67 | |
| Stock based compensation to revenue | 0 | 0 | 1.29 | 0 | 0 | |
| Graham number | 3.12 | 6.85 | 17.75 | 25.62 | 30.09 | |
| ROIC | 0.51 | 0.66 | -0.15 | 0.19 | -0.38 | |
| Return on tangible assets | -0.2 | -0.24 | -0.15 | 0.2 | -0.32 | |
| Graham Net | -0.96 | -1.86 | 14.67 | 18.49 | 10.52 | |
| Working capital | 97.57M | 197.96M | 284.82M | 451.97M | 452.05M | |
| Tangible asset value | -39.91M | -76.34M | 425.37M | 535.03M | 453.9M | |
| Net current asset value | -40.28M | -78.77M | 284.75M | 448.38M | 448.99M | |
| Invested capital | 0 | 0 | 0 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 2.7M | |
| Average payables | 615K | 5.31M | 6.42M | 2.91M | 2.58M | |
| Average inventory | 0 | 0 | 0 | 0 | -2.7M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 4.87K | 56.98K | 21.82K | 10.44K | 2.94K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | -6.36K | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.07 | 0.01 | 0.02 | 0.03 | 0.12 | |
| Inventory turnover | 0 | 0 | 0 | 0 | -0.06 | |
| ROE | 0.49 | 0.65 | -0.15 | 0.21 | -0.34 | |
| Capex per share | 0 | 0 | -0.01 | -0.03 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.59 | -1.42 | -0.81 | -0.92 | -0.56 | |
| Operating cash flow per share | -0.55 | -1.25 | -0.78 | -0.8 | -0.42 | |
| Free cash flow per share | -0.57 | -1.26 | -0.78 | -0.8 | -0.42 | |
| Cash per share | 18.82 | 9.6 | 21.58 | 10.91 | 10.91 | |
| Book value per share | 11.69 | 11.94 | 12.5 | 10.97 | 10.6 | |
| Tangible book value per share | 11.69 | 11.94 | 12.5 | 10.97 | 10.61 | |
| Share holders equity per share | 11.69 | 11.94 | 12.5 | 10.97 | 10.6 | |
| Interest debt per share | 0.04 | 0.05 | 0.16 | 0.14 | 0.08 | |
| Market cap | 482.67M | 416.18M | 429.88M | 386.74M | 436.07M | |
| Enterprise value | -62.26M | 300.62M | -75.96M | 327.81M | 341.23M | |
| P/E ratio | -4.45 | -1.8 | -3.34 | -2.47 | -4.58 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -19.32 | -8.16 | -13.86 | -11.33 | -24.05 | |
| PFCF ratio | -18.66 | -8.14 | -13.84 | -11.33 | -24.05 | |
| P/B Ratio | 0.9 | 0.86 | 0.86 | 0.82 | 0.96 | |
| PTB ratio | 0.9 | 0.86 | 0.86 | 0.82 | 0.96 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 1.91 | -4.8 | 2.02 | -7.4 | -7.51 | |
| EV to operating cash flow | 2.49 | -5.89 | 2.45 | -9.6 | -18.82 | |
| EV to free cash flow | 2.41 | -5.88 | 2.45 | -9.6 | -18.82 | |
| Earnings yield | -0.06 | -0.14 | -0.07 | -0.1 | -0.05 | |
| Free cash flow yield | -0.05 | -0.12 | -0.07 | -0.09 | -0.04 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 16.71 | 1.84 | 13.45 | 1.33 | 2.09 | |
| Current ratio | 21.09 | 15.25 | 26.03 | 20.33 | 17.07 | |
| Interest coverage | 10.04 | 13.6 | 0 | 0 | 0 | |
| Income quality | 0.92 | 0.88 | 0.96 | 0.87 | 0.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.04 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -14.95 | -2.21 | -0.6 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 12.48 | 19.56 | 15.06 | 15.04 | 11.52 | |
| ROIC | -0.06 | -0.13 | -0.06 | -0.08 | -0.06 | |
| Return on tangible assets | -0.05 | -0.11 | -0.06 | -0.08 | -0.05 | |
| Graham Net | 18.25 | 8.88 | 21.02 | 10.31 | 10.22 | |
| Working capital | 451.97M | 372.86M | 492.44M | 453.27M | 452.05M | |
| Tangible asset value | 535.03M | 485.65M | 499.57M | 468.82M | 453.9M | |
| Net current asset value | 448.38M | 369.69M | 489.71M | 450.82M | 448.99M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 2.7M | |
| Average payables | 2.09M | 2.35M | 2.26M | 1.72M | 1.72M | |
| Average inventory | 0 | 0 | 0 | 0 | -2.7M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 4.06K | 2.54K | 2.77K | 1.07K | 2.91K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | -6.31K | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.02 | 0.04 | 0.03 | 0.08 | 0.03 | |
| Inventory turnover | 0 | 0 | 0 | 0 | -0.01 | |
| ROE | -0.05 | -0.12 | -0.06 | -0.08 | -0.05 | |
| Capex per share | -0.02 | 0 | 0 | 0 | 0 |
CGEM Frequently Asked Questions
What is Cullinan Oncology, Inc. stock symbol ?
Cullinan Oncology, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol CGEM
What is Cullinan Oncology, Inc. stock quote today ?
Cullinan Oncology, Inc. stock price is $17.88 today.
Is Cullinan Oncology, Inc. stock public?
Yes, Cullinan Oncology, Inc. is a publicly traded company.
Company Profile
- Volume Average 431.84K
- Market Capitalization 717.9M
- Employee 85
- CEO Mr. Nadim Ahmed
- Headquarters Cambridge,MA,US
- IPO Date 2021-01-08
-
Website
https://www.cullinanoncology.com 
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
